Physician profile
Victor G Carabello
NPI 1649293705
$363,444.91
in general payments reported to CMS, 2019-2025
51 companies · $91K in 2025
The $91K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,043 · 2020: $2,914 · 2021: $3,976 · 2022: $56K · 2023: $126K · 2024: $80K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $142K · Honoraria: $81K · Travel and Lodging: $38K · Food and Beverage: $21K · Consulting Fee: $9,263 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,600 · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,679.76 |
| Honoraria | $81,400.00 |
| Travel and Lodging | $37,602.54 |
| Food and Beverage | $21,031.65 |
| Consulting Fee | $9,262.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,600.00 |
| Education | $478.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $86,177.02 | 2019-2023 | Krystexxa |
| Amgen INC. | $74,581.54 | 2019-2025 | Krystexxa, Repatha, Tavneos |
| Novo Nordisk INC | $65,531.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $62,365.26 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $34,123.18 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $14,486.11 | 2022-2025 | Filspari |
| Sobi, INC | $4,552.43 | 2024 | |
| Novartis Pharmaceuticals Corporation | $3,601.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,162.54 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Mallinckrodt Hospital Products INC. | $1,839.44 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $1,763.17 | 2019-2025 | Auryxia, Vafseo |
| Merck Sharp & Dohme LLC | $1,488.88 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $1,207.75 | 2019-2023 | |
| Vifor Pharma, INC. | $992.05 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $967.38 | 2019-2025 | Velphoro, Korsuva, Velphoro |
Show all 49 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Carabello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.